Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Biotech
AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF race
AbbVie has made no secret of the fact that it's taken an interest in the hotly contested PD-1xVEGF bispecific space. Now, it's diving in.
James Waldron
Jan 12, 2026 11:00am
InduPro nabs 2nd Big Pharma deal with $950M Lilly pact
Jan 7, 2026 3:52pm
Ipsen's ADC push leads to $1B deal for preclinical Simcere drug
Dec 22, 2025 7:15am
Daiichi-Merck ph. 3 ADC program on pause after patient deaths
Dec 18, 2025 11:22am
2 biotechs run out of road
Dec 17, 2025 11:38am
Crescent inks $80M Kelun deal, adding ADC to mix with bispecific
Dec 4, 2025 9:50am
